A phase 0 study of KAND 567 inpatients with lymphoma
Phase of Trial: Phase 0
Latest Information Update: 07 Dec 2018
At a glance
- Drugs KAND-567 (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 07 Dec 2018 New trial record
- 23 Nov 2018 According to a Kancera media release, the company is conducting this phase 0 study in collaboration with Karolinska Hospital and the Institute.
- 23 Nov 2018 According to a Kancera media release, the company expects to complete the enrollment in this study in Dec 2018 and the analysis are expected to complete in Jan 2019.